Location

Georgia

Start Date

16-5-2017 1:00 PM

Description

According to the CDC’s National Center for Health Statistics, more than one-third (36.5%) of U.S adults are obese. It is the main risk factor for type-2-diabetes, hypertension, dyslipidemia and atherosclerosis. Nutraceuticals such as Xanthohumol have shown potential to inhibit adipogeneis, however, their bioavailability has remained controversial. Hence there is a need to develop targeted therapy which will increase the concentration of Xanthohumol on adipose tissues. Currently, magnetic drug delivery has been used to develop targeted therapies where conventional therapies have proven to be less effective. Among various types of nanoparticles ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) have found considerable attention in magnetic drug delivery as they are easy to synthesize, inert, and are biocompatible. Hence to deliver Xanthohumol to adipose tissues we synthesized USPIO tagged Xanthohumol. The synthesized USPIO nanoparticles were amine functionalized using 3-aminotripropyl ethoxysilane. The presence of amine functional groups on the surface of USPIO was confirmed qualitatively using FTIR and quantitatively using ninhydrin Assay. The ninhydrin assay revealed that 1 mg of amine functionalized UPSIO had 22mg of amine groups. Xanthohumol was then conjugated to the surface of amine-USPIO using via a polyethylene glycol linker. The presence of Xanthohumol on the surface of nanoparticles was confirmed via FTIR. The amount of Xanthohumol tagged onto the surface of doped nanoparticles was quantified using HPLC. The particle size of the synthesized nanoparticles will be evaluated using TEM and the toxicity and therapeutic potency of Xanthohumol tagged to USPIO will be evaluated in vitro.

Embargo Period

6-26-2017

COinS
 
May 16th, 1:00 PM

Magnetic Drug Delivery of Xanthohumol to Adipocytes Using Ultrasmall Superparamagnetic Iron Oxide Nanoparticles.

Georgia

According to the CDC’s National Center for Health Statistics, more than one-third (36.5%) of U.S adults are obese. It is the main risk factor for type-2-diabetes, hypertension, dyslipidemia and atherosclerosis. Nutraceuticals such as Xanthohumol have shown potential to inhibit adipogeneis, however, their bioavailability has remained controversial. Hence there is a need to develop targeted therapy which will increase the concentration of Xanthohumol on adipose tissues. Currently, magnetic drug delivery has been used to develop targeted therapies where conventional therapies have proven to be less effective. Among various types of nanoparticles ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) have found considerable attention in magnetic drug delivery as they are easy to synthesize, inert, and are biocompatible. Hence to deliver Xanthohumol to adipose tissues we synthesized USPIO tagged Xanthohumol. The synthesized USPIO nanoparticles were amine functionalized using 3-aminotripropyl ethoxysilane. The presence of amine functional groups on the surface of USPIO was confirmed qualitatively using FTIR and quantitatively using ninhydrin Assay. The ninhydrin assay revealed that 1 mg of amine functionalized UPSIO had 22mg of amine groups. Xanthohumol was then conjugated to the surface of amine-USPIO using via a polyethylene glycol linker. The presence of Xanthohumol on the surface of nanoparticles was confirmed via FTIR. The amount of Xanthohumol tagged onto the surface of doped nanoparticles was quantified using HPLC. The particle size of the synthesized nanoparticles will be evaluated using TEM and the toxicity and therapeutic potency of Xanthohumol tagged to USPIO will be evaluated in vitro.